Drugs / CD07223
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01106807 | Apr → Sep 2010 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01670032 | Aug 2012 → Aug 2013 | impetigo | NovaBay Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD 07223 | “A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo” NCT01670032 ↗ |
| Route | Topical | “500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks” NCT01106807 ↗ |